#ASCO22 – Phase 2 single-arm study: Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation.
6 Jun, 2022 | 11:15h | UTCAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute